XLV - Health Care Select Sector SPDR ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
90.76
-0.75 (-0.82%)
At close: 4:00PM EDT

90.76 0.00 (0.00%)
After hours: 4:52PM EDT

Stock chart is not supported by your current browser
Previous Close91.51
Open91.50
Bid0.00 x 1400
Ask0.00 x 3000
Day's Range90.34 - 91.67
52 Week Range78.74 - 96.06
Volume8,288,278
Avg. Volume8,146,537
Net Assets19.61B
NAV95.11
PE Ratio (TTM)N/A
Yield1.38%
YTD Return16.36%
Beta (3Y Monthly)0.93
Expense Ratio (net)0.14%
Inception Date1998-12-16
Trade prices are not sourced from all markets
  • Healthcare stocks are surging ahead of the mid-term elections
    Yahoo Finance Video21 days ago

    Healthcare stocks are surging ahead of the mid-term elections

    Healthcare stocks have been on fire recently, with the SPDR Healthcare Select Sector ETF surging nearly 15 percent over the past 3 months alone.

  • Pfizer Reported Revenue Growth in Global Markets
    Market Realist3 days ago

    Pfizer Reported Revenue Growth in Global Markets

    Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.

  • Top-Ranked Healthcare ETFs for Long-Term Investors
    Zacks4 days ago

    Top-Ranked Healthcare ETFs for Long-Term Investors

    Healthcare is now the best-performing sector of 2018. We highlight two top-ranked ETFs suitable for long-term investors.

  • Investor's Business Daily5 days ago

    Best ETFs: SPDR Health Care ETF Stands Alone In This Key Trait

    Health Care Select Sector SPDR stood out among the best ETFs as it was the only of 28 members of IBD's ETF Leaders screen trading above its 50-day moving average.

  • ETF Trends6 days ago

    Healthcare ETFs’ Quarterly Checkup Looks Healthy

    Strong earnings results from healthcare giants are supporting a rally in the defensive sector-related exchange traded funds. On Tuesday, the Health Care Select Sector SPDR (NYSEArca: XLV) gained 2.5%. ...

  • MarketWatch6 days ago

    A popular health-care fund is on pace for its best day since President Trump's election

    A popular way to bet on the health-care sector, the Health Care Select Sector SPDR ETF , Tuesday afternoon was on track for its best daily gain since November of 2016. The exchange-traded fund was up 2.2% in afternoon action, putting it on pace for its sharpest single-session rise since a 3.4% surge on Nov. 9, according to Dow Jones Market Data. That was the day after Trump was elected. Tuesday's moves for the so-called "XLV" fund, a reference to its ticker symbol, is supported by a jump in shares of UnitedHealth Group Inc. , which posted better-than-expected quarterly results before the official start of trading, along with Johnson & Johnson . Gains in health-care were helping to lift the broader market (along with information technology), with the Dow Jones Industrial Average gaining more than 400 points or 1.6%, the S&P 500 index up by 1.6% and the Nasdaq Composite Index advancing by 2.2%.

  • MarketWatch6 days ago

    All 11 sectors of the S&P 500 trade firmly higher in tech-inspired afternoon rally

    All of the S&P 500 index sectors on Tuesday were trading in positive territory, and 10 of those sectors boast gains of at least 1%, led by 2.3% surge in the information technology sector. The S&P 500 index was up 1.6% at 2,794, trading at around session highs, with the tech sector up 2.5%, and health-care stocks rallying by 2.2%. The tech-heavy Nasdaq Composite Index , meanwhile, was up 2.1% at 7,589 and the Dow Jones Industrial Average climbed by more than 400 points or 1.6% at 25,656. A day earlier technology and internet-related shares led U.S. stocks to modest losses. On Tuesday, Wall Street stocks, after a mostly downbeat stretch for equity benchmarks, were rising on the back of a strong round of quarterly corporate resulst from banks Goldman Sachs Group Inc. , Morgan Stanley , and health-care names UnitedHealth Group Inc. and Johnson & Johnson .

  • InvestorPlace6 days ago

    7 Best ETFs to Buy Now for Defensive Stocks

    With seasonal volatility, rising interest rates, uncertainty over a tariff war with China and fast-approaching mid-term elections all on the minds of investors, the best ETFs to buy now are those that invest in defensive areas of the market.

  • How Is Medtronic Positioned in October?
    Market Realist7 days ago

    How Is Medtronic Positioned in October?

    In the first quarter of fiscal 2019, Medtronic generated net revenues of $7.4 billion, a ~0.1% year-over-year (or YoY) decline. Wall Street analysts estimate that Medtronic will generate revenues of $7.3 billion in the second quarter of fiscal 2019.

  • MarketWatch11 days ago

    Pfizer to pay $700,000 to settle 'deceptive advertising' charges; stock drops to pace Dow losers

    Pfizer Inc. will pay over $700,000 to settle charges for "deceptive advertising," according to a statement from New York Attorney General Barbara Underwood. Pfizer's stock dropped 2.7% in morning trade, enough to pace the Dow Jones Industrial Average's decliners. Pfizer's payment includes over $200,000 in restitution for New York consumers and $500,000 in penalties, feels and costs. The company had promised consumers they would pay no more than a $15 to $20 for certain drugs, but many ended up spending far more than that. The stock was still up 16.5% over the past three months, while the SPDR Health Care Select Sector ETF has gained 5.8% and the Dow has tacked on 3.2%.

  • ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
    Market Realist11 days ago

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close. On the day, Morgan Stanley raised its target price on ABT stock from $70 to $80. However, the stock price dropped as the broader market sell-off pulled down ABT stock prices along with a large number of other healthcare stocks. The SPDR S&P 500 ETF (SPY) was down ~3.2% on October 10.

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist11 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Investopedia12 days ago

    Top 3 Healthcare Stocks for 2018

    The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.

  • ETF Trends12 days ago

    Health Care ETFs Retreat on DOJ Approval of Aetna-CVS Merger

    The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist12 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.

  • MarketWatch13 days ago

    Mylan downgraded as previous bullish thesis is now 'broken'

    Shares of Mylan N.V. dropped 1.4% toward a one-year low in afternoon trade Tuesday, after the drug maker was downgraded at Morgan Stanley on concerns over generic sales trends, risks to EpiPen from generic competition and biosimilars strategy that's less compelling that expected. Analyst David Risinger cut his rating to equal weight, saying his thesis for upgrading the stock to overweight in March is now "broken." He lowered his stock price target to $36, which is 3.1% above current levels, from $42. Back in March 2018 when we upgraded [Mylan] from EW to OW, we expected solid growth prospects versus peers, differentiated pipeline progress and positive catalysts," Risinger wrote in a note to clients. "But newsflow has disappointed, and we fear further pressure even though we still expect Mylan to receive FDA approval of its generic Advair imminently." The stock has shed 17.7% year to date, while the SPDR Health Care Select Sector ETF has rallied 14.5% and the S&P 500 has gained 8.0%.

  • Allergan’s Neurology Portfolio, Stock Performance, and Ratings
    Market Realist13 days ago

    Allergan’s Neurology Portfolio, Stock Performance, and Ratings

    On October 3, Allergan’s (AGN) stock price closed at $193.46, which is ~11.0% below its 52-week high of $215.10 on October 3, 2017. Allergan’s stock price grew from $164.05 at the open of the market on January 2 to $193.46 on October 3, which reflects ~18.0% YTD (year-to-date) growth. On March 5, Merck hit its 52-week low of $142.81.

  • ETF Trends14 days ago

    Traders Prep For a Pullback in a Big Healthcare ETF

    The Health Care Select Sector SPDR (XLV) , the largest healthcare exchange traded fund by assets, and rival healthcare ETFs have spent much of 2018 in rally mode, but that is not stopping some traders from betting on a near-term pullback for the high-flying sector. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks. There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up.

  • US Unemployment at 49-Year Low: How Did the Markets React?
    Market Realist17 days ago

    US Unemployment at 49-Year Low: How Did the Markets React?

    The US jobs report for September was released on October 5. While the jobs report was mixed, there were enough signs that the labor market was tightening, which would eventually lead to wage growth gains.

  • UnitedHealth Group Stock Hit 52-Week High on October 3
    Market Realist18 days ago

    UnitedHealth Group Stock Hit 52-Week High on October 3

    UNH Stock Hits 52-Week High: Can It Sustain the Momentum?UnitedHealth Group’s recent trading activity

  • Top Performing ETFs of the Third Quarter
    Zacks18 days ago

    Top Performing ETFs of the Third Quarter

    Healthcare emerged as the new leader in Q3. Here is what investors need to know about best performing sectors and ETFs.

  • Job Growth in September Could Surprise to the Upside
    Market Realist18 days ago

    Job Growth in September Could Surprise to the Upside

    Economists expect the US economy to add 180,000 jobs in September—below the 201,000 job additions reported in August and the average monthly gain of 196,000 over the previous 12 months. Economists’ estimate for job additions could have an upside, according to data from ADP and Moody’s Analytics. Based on the data released on October 3, private companies added 230,000 more jobs in September—much higher than the expectations of 184,000 jobs. The job additions were the highest level since 241,000 job additions in February.

  • MarketWatch18 days ago

    Eli Lilly's stock surges toward record after positive trials for diabetes treatments

    Shares of Eli Lilly & Co. rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and GLP-1 receptor agonist showed "strong and clinically meaningful blood sugar reduction and weight loss" in people with type 2 diabetes. "These phase 2b clinical trial results for GIP/GLP-1 RA are unprecedented, and the impressive blood glucose and weight reductions seen may lead to a new treatment option for people with type 2 diabetes," said Juan Frias, principal investigator at the National Research Institute. Separately, Lilly and Boehringer Ingelheim said a phase 3 trial of its type 1 diabetes treatment met its primary endpoint. Lilly's stock has soared 25.6% over the past three months, while the SPDR Health Care Select Sector ETF has climbed 13.6% and the Dow Jones Industrial Average has gained 11.0%.

  • Investopedia20 days ago

    6 Health Care Stocks Poised For Healthy Gains

    Health care stocks posted major gains in the latest quarter, leaving many other sectors in the dust. Performance like that has propelled the S&P 500 health care ETF ( XLV) upward by 13% year-to-date (YTD) through Monday's close, compared to the broader S&P 500's 9.4% return over the same period, as industry players such as Biogen Inc. ( BIIB), Eli Lilly and Co. ( LLY) and Pfizer Inc. ( PFE) drive the sector's outperformance. Healthcare bulls expect electoral results to favor the outlook for policies beneficial to a wide range of healthcare related companies.

  • Mylan Stock Declined ~12% Year-to-Date: Could It Recover Soon?
    Market Realist21 days ago

    Mylan Stock Declined ~12% Year-to-Date: Could It Recover Soon?

    The closing price for Mylan (MYL) stock on September 25 was $23.27, and its market capitalization stood at $19.4 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $30.73 on September 28. Currently, Mylan stock is trading above its 50-day moving average of $23.18 as well as its 200-day moving average of $21.39.